AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
- SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development. - Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
- Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
- AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.